Mesenchymal stem cell-derived exosomes regulate microglia phenotypes: a promising treatment for acute central nervous system injury

• Published in: Neural regeneration research Vol. 18; no. 8; pp. 1657 - 1665
• Main Authors: Liu, Yu-Yan, Li, Yun, Wang, Lu, Zhao, Yan, Yuan, Rui, Yang, Meng-Meng, Chen, Ying, Zhang, Hao, Zhou, Fei-Hu, Qian, Zhi-Rong, Kang, Hong-Jun
• Format: Journal Article
• Language: English
• Published: India Department of Critical Care Medicine,the First Medical Center,Chinese PLA General Hospital,Beijing,China%Department of Critical Care Medicine,the First Medical Center,Chinese PLA General Hospital,Beijing,China%Beidou Precision Medicine Insititute,Guangzhou,Guangdong Province,China 01.08.2023; Medical School of Chinese PLA,Beijing,China; Wolters Kluwer - Medknow
• Subjects: Review; mesenchymal stem cell; molecular mechanism; central nervous system inflammation; neuroinflammation; microglia phenotypic transformation; mesenchymal stem cell-derived exosomes (MSC-Exos); microglia activation; acute CNS injury; exosome; immune regulation
• ISSN: 1673-5374; 1876-7958
• DOI: 10.4103/1673-5374.363819

There is growing evidence that long-term central nervous system (CNS) inflammation exacerbates secondary deterioration of brain structures and functions and is one of the major determinants of disease outcome and progression. In acute CNS injury, brain microglia are among the first cells to respond and play a critical role in neural repair and regeneration. However, microglial activation can also impede CNS repair and amplify tissue damage, and phenotypic transformation may be responsible for this dual role. Mesenchymal stem cell (MSC)-derived exosomes (Exos) are promising therapeutic agents for the treatment of acute CNS injuries due to their immunomodulatory and regenerative properties. MSC-Exos are nanoscale membrane vesicles that are actively released by cells and are used clinically as circulating biomarkers for disease diagnosis and prognosis. MSC-Exos can be neuroprotective in several acute CNS models, including for stroke and traumatic brain injury, showing great clinical potential. This review summarized the classification of acute CNS injury disorders and discussed the prominent role of microglial activation in acute CNS inflammation and the specific role of MSC-Exos in regulating pro-inflammatory microglia in neuroinflammatory repair following acute CNS injury. Finally, this review explored the potential mechanisms and factors associated with MSC-Exos in modulating the phenotypic balance of microglia, focusing on the interplay between CNS inflammation, the brain, and injury aspects, with an emphasis on potential strategies and therapeutic interventions for improving functional recovery from early CNS inflammation caused by acute CNS injury.